Brief: Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA
07/04/2026 13:55
April 7 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS ANNOUNCES FORMAL DISPUTE RESOLUTION REQUEST FOR ONS-5010/LYTENAVA™ (BEVACIZUMAB-VIKG) ACCEPTED BY FDA OUTLOOK THERAPEUTICS INC - FDA ACCEPTS OUTLOOK THERAPEUTICS' DISPUTE RESOLUTION REQUEST FOR ONS-5010/LYTENAVA; MEETING IN APRIL 2026 Source text: ID:nGNX286GBP Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce